Literature DB >> 23760443

[Systemic therapy of rosacea].

M Schaller1, K Belge.   

Abstract

The only medication which is authorized for therapy of rosacea is doxycycline. It is usually administered at a dose of 40-100 mg daily for 3-6 months. In case of a lack of efficacy or in case of contraindications (e.g. pregnancy, children below 8 years), azithromycin or metronidazole are alternative systemic therapies. Those forms of rosacea which involve hyperplasia of sebaceous glands respond well to retinoids such as isotretinoin. Dapsone has been successfully used for the treatment of granulomatous rosacea and rosacea fulminans. Erythema can be reduced by use of beta blockers. If patients do not respond to various therapies or if they are immunocompromised, the differential diagnosis of demodicosis should be considered; here the treatment is oral ivermectin. Some forms of rosacea (rosacea fulminans and granulomatous rosacea) may be treated initially with oral corticosteroids. Ophthalmic rosacea is treated topically as well as with tetracyclines or macrolides.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23760443     DOI: 10.1007/s00105-012-2519-4

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  30 in total

Review 1.  Clinical and histological variants of rhinophyma, including nonsurgical treatment modalities.

Authors:  T Jansen; G Plewig
Journal:  Facial Plast Surg       Date:  1998       Impact factor: 1.446

2.  Systemic isotretinoin in the treatment of rosacea - doxycycline- and placebo-controlled, randomized clinical study.

Authors:  Harald Gollnick; Ulrike Blume-Peytavi; Eörs Lāszlō Szabó; Karl-Gustav Meyer; Petra Hauptmann; Georg Popp; Michael Sebastian; Thomas Zwingers; Christoph Willers; Renate von der Weth
Journal:  J Dtsch Dermatol Ges       Date:  2010-03-12       Impact factor: 5.584

3.  Rosacea.

Authors:  Katharina Gauwerky; Winfried Klövekorn; Hans Christian Korting; Percy Lehmann; Eva-Maria Meigel; Dieter Reinel; Thomas Ruzicka; Martin Schaller; Helmut Schöfer; Julia Tietze
Journal:  J Dtsch Dermatol Ges       Date:  2009-11       Impact factor: 5.584

Review 4.  [Rosacea 2009 : new advances in pathophysiology, clinical staging and therapeutic strategies].

Authors:  A Sobottka; P Lehmann
Journal:  Hautarzt       Date:  2009-12       Impact factor: 0.751

5.  Efficacy of low-dose isotretinoin in patients with treatment-resistant rosacea.

Authors:  F G Erdogan; P Yurtsever; D Aksoy; F Eskioglu
Journal:  Arch Dermatol       Date:  1998-07

6.  Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream.

Authors:  C Forstinger; H Kittler; M Binder
Journal:  J Am Acad Dermatol       Date:  1999-11       Impact factor: 11.527

7.  Symptomatic treatment of idiopathic and rosacea-associated cutaneous flushing with propranolol.

Authors:  Helen Craige; Jack B Cohen
Journal:  J Am Acad Dermatol       Date:  2005-11       Impact factor: 11.527

Review 8.  Diagnosis and treatment of rosacea fulminans.

Authors:  T Jansen; G Plewig; A M Kligman
Journal:  Dermatology       Date:  1994       Impact factor: 5.366

9.  Demodex abscesses: clinical and therapeutic challenges.

Authors:  Martin Schaller; Christian A Sander; Gerd Plewig
Journal:  J Am Acad Dermatol       Date:  2003-11       Impact factor: 11.527

10.  Oral azithromycin for treatment of intractable rosacea.

Authors:  Jae-Hong Kim; Yoon Seok Oh; Eung Ho Choi
Journal:  J Korean Med Sci       Date:  2011-04-21       Impact factor: 2.153

View more
  2 in total

Review 1.  [Acne and rosacea in pregnancy].

Authors:  S K Bechstein; F Ochsendorf
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

Review 2.  [Retinoids in dermatopharmacology].

Authors:  P M Amann; H F Merk; J M Baron
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.